Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $1.12.
According to TipRanks, Rahimi is a 4-star analyst with an average return of 3.3% and a 32.98% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Cytokinetics, Prothena, and aTyr Pharma.
Currently, the analyst consensus on Lexicon Pharmaceuticals is a Moderate Buy with an average price target of $7.50.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.79 and a one-year low of $0.96. Currently, Lexicon Pharmaceuticals has an average volume of 1.81M.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LXRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lexicon Pharmaceuticals (LXRX) Company Description:
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Read More on LXRX:
- Lexicon gets preferred status with Express Scripts for Medicare patients
- INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
- Lexicon appoints Tom Garner as SVP, CCO
- Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
- Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
